- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.10. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 29.09. | Halberd Corp.: Halberd Corporation Acquires NeuroSense AI Corp., a Revolutionary Behavioral Intelligence Platform to Transform TBI, Other Research, and Clinical Assessment | 1 | GlobeNewswire (USA) | ||
| 25.09. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 10.09. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| NEUROSENSE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 10.09. | NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons | 109 | PR Newswire | Initial Phase 2 RoAD trial results demonstrate improvements in brain-cell connectivity and health, with a favorable safety profile
CAMBRIDGE, Mass., Sept. 10... ► Artikel lesen | |
| 08.09. | RECIPHARM AB: Recipharm partners with NeuroSense Therapeutics to advance ALS therapy PrimeC toward Phase 3 trials | 3 | Cision News | ||
| 04.09. | NeuroSense Therapeutics announces $500,000 private placement | 1 | Seeking Alpha | ||
| 02.09. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 20.08. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 15.08. | NeuroSense Therapeutics Ltd. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 01.08. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 10.07. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 26.06. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 12.05. | This NeuroSense Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Monday | 20 | Benzinga.com | ||
| 12.05. | Boral Capital starts NeuroSense stock with Buy, $14 target | 12 | Investing.com | ||
| 07.05. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 24.04. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 24.04. | NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update | 171 | PR Newswire | Letter outlines Phase 3 timeline for PrimeC in ALS, provides update on Canadian regulatory pathway and strategic partnership discussions; Company optimistic about... ► Artikel lesen | |
| 09.04. | NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment | 291 | PR Newswire | New miRNA findings unveiled at the AAN, reveal key biological mechanisms behind PrimeC's clinical benefit in ALS.
CAMBRIDGE, Mass., April 9, 2025 /PRNewswire/... ► Artikel lesen | |
| 07.04. | NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates | 163 | PR Newswire | Phase 2b study completed in amyotrophic lateral sclerosis (ALS) demonstrated lead asset PrimeC slows disease progression and functional decline
Ongoing partnership... ► Artikel lesen |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CARDIOL THERAPEUTICS | 0,890 | -2,41 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
12.08.2025 / 13:31 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen | |
| CIDARA THERAPEUTICS | 87,50 | -3,85 % | Cidara Therapeutics, Inc.: Cidara Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for CD388 in Seasonal Influenza Prevention | SAN DIEGO, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics... ► Artikel lesen | |
| QIAGEN | 41,225 | +1,41 % | QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast | QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025.
Press release date time: Tuesday, November 4, shortly after 22:05... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 162,59 | +183,70 % | Studienerfolg bei Tremor-Medikament: Aktie von Praxis Precision Medicines explodiert, Oppenheimer verdoppelt Kursziel | ||
| AVIDITY BIOSCIENCES | 48,780 | -3,39 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026 | SAN DIEGO, Oct. 13, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 6,355 | -6,68 % | Recursion Pharmaceuticals (RXRX) Extends Gains, Jumps 15.28% on Major AI Event | ||
| ADMA BIOLOGICS | 14,560 | -3,58 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| CG ONCOLOGY | 41,850 | -2,72 % | Why Cg Oncology Stock Rocketed 7% Higher Today | ||
| ARCUTIS BIOTHERAPEUTICS | 20,910 | -3,28 % | Arcutis Biotherapeutics, Inc.: FDA Approves Arcutis' ZORYVE (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5 | ZORYVE cream 0.05% provides rapid and effective relief of mild to moderate atopic dermatitis in children ages 2 to 5 and is safe and well toleratedOnce-daily, steroid-free cream can be used anywhere... ► Artikel lesen | |
| EVOTEC | 6,876 | +2,20 % | BioNxt Solutions, Bayer, Evotec - Enormes Upside! Schnittstelle von Biotech und Pharma! | Die weltweite Zunahme von Wohlstandserkrankungen wie Diabetes, Adipositas, Multipler Sklerose (MS) und MASH (metabolisch bedingte Fettleber) sorgt für ein enormes Wachstum im Gesundheitssektor. Ebenso... ► Artikel lesen | |
| BIONTECH | 89,90 | +0,39 % | BioNTech Aktie: Jetzt kommt die Wende! | © Foto: Foto von CDC auf Unsplash (Symbolbild)Die BioNTech-Aktie steht vor einem spannenden Wendepunkt. Nach turbulenten Zeiten hat sich der Kurs stabilisiert und zeigt erste Anzeichen einer nachhaltigen... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 21,990 | -2,91 % | Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025 | Conference Call to be Held at 8:00am ET
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") will host an ESMO Data Update and Third Quarter Earnings Call on Monday, October... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 10,110 | -7,76 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy (epinephrine nasal spray) | SAN DIEGO, Oct. 08, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial-stage biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 42,980 | -0,83 % | Mineralys Therapeutics: Aktie erreicht Rekordhoch von 41,11 USD | ||
| QUANTUM-SI | 2,535 | -3,61 % | Why Quantum-Si Stock Flopped on Friday |
NEUROSENSE THERAPEUTICS LTD gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,010 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEUROSENSE THERAPEUTICS LTD finden Sie auf Wallstreet Online.